Recent developments in ocular drug delivery

References

• Lens A, Nemeth SC, Ledford JK. Ocular anatomy and physiology. New Jersey: Slack Incorporated; 2008
   Google Scholar
• Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010;12:348–60
   PubMed Web of Science ®Google Scholar
• Molokhia SA, Thomas SC, Garff KJ, et al. Anterior eye segment drug delivery systems: current treatments and future challenges. J Ocul Pharmacol Ther 2013;29:92–104
   PubMed Web of Science ®Google Scholar
• Patel PB, Shastri DH, Shelat PK, Shukla AK. Ophthalmic drug delivery system: challenges and approaches. Syst Rev Pharm 2010;1:113–20
   Google Scholar
• Cholkar K, Patel SP, Vadlapudi AD, Mitra AK. Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther 2013;29:106–23
   PubMed Web of Science ®Google Scholar
• Singh V, Ahmad R, Heming T. The challenges of ophthalmic drug delivery: a review. Int J Drug Discov 2011;3:56–62
   Google Scholar
• Karen S. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008;31:213–24
   PubMed Web of Science ®Google Scholar
• Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995;26:233–6
   PubMedGoogle Scholar
• Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 2005;112:953–61
   PubMed Web of Science ®Google Scholar
• Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 2005;57:1595–639
   PubMed Web of Science ®Google Scholar
• Agrawal RV, Murthy S, Sangwan V, Biswas J. Current approach in diagnosis and management of anterior uveitis. Indian J Ophthalmol 2010;58:11–19
   PubMed Web of Science ®Google Scholar
• Syed BA, Kumar S, Bielory L. Current options and emerging therapies for anterior ocular inflammatory disease. Curr Opin Allergy Clin Immunol 2014;14:485–9
   PubMed Web of Science ®Google Scholar
• Lin H, Yiu SC. Dry eye disease: a review of diagnostic approaches and treatments. Saudi J Ophthalmol 2014;28:173–81
   PubMedGoogle Scholar
• Wentz SM, Kim NJ, Wang J, et al. Novel therapies for open-angle glaucoma. F1000Prime Rep 2014;6:102–7
   PubMedGoogle Scholar
• Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs 2008;68:1029–36
   PubMed Web of Science ®Google Scholar
• Kuno N, Fujii S. Ocular drug delivery systems for the posterior segment: a review. Retina Today 2012;May/June:54–9
   Google Scholar
• Lai K, Landa G. Current choice of treatments for neovascular AMD. Expert Rev Clin Pharmacol 2015;8:135–40
   PubMed Web of Science ®Google Scholar
• Zhang X, Zeng H, Bao S, et al. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci 2014;4:27–40
   PubMed Web of Science ®Google Scholar
• Song SJ, Wong TY. Current concepts in diabetic retinopathy. Diabetes Metab J 2014;38:416–25
   Google Scholar
• Arevalo JF. Diabetic macular edema: changing treatment paradigms. Curr Opin Ophthalmol 2014;25:502–7
   PubMed Web of Science ®Google Scholar
• Boyer DS, Faber D, Gupta S, et al., Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31:915–23
   PubMed Web of Science ®Google Scholar
• Cabrera M, Yeh S, Albini TA. Sustained-release corticosteroid options. J Ophthalmol 2014;2014: 164692. doi:10.1155/2014/164692
   PubMed Web of Science ®Google Scholar
• Hunter RS, Lobo AM. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin Ophthalmol 2011;5:1613–21
   PubMedGoogle Scholar
• Kompella UB, Kadam RS, Lee VHL. Recent advances in ophthalmic drug delivery. Ther Deliv 2010;1:435–56
   PubMedGoogle Scholar
• Gupta C, Chauhan A. Ophthalmic delivery of cyclosporine A by punctal plugs. J Control Release 2011;150:70–6
   PubMed Web of Science ®Google Scholar
• Butchofsky B. Punctal plug delivery system: sustained drug delivery for ophthalmology. Ophthalmology Innovation Summit; 2014; Chicago, IL
   Google Scholar
• Juan Jr ED, Boyd S, Reich C, et al., inventors; QLT Inc., assignee. Nasolacrimal drainage system implants for drug therapy. US patent 7,998,497 B2;2011
   Google Scholar
• Jessen BA, Shiue MH, Kaur H, et al. Safety assessment of subconjunctivally implanted devices containing latanoprost in Dutch-belted rabbits. J Ocul Pharmacol Ther 2013;29:574–85
   PubMed Web of Science ®Google Scholar
• Allergan Investor Presentation June 30, 2014. 2014. Available from: http://www.allergan.com/assets/pdf/investor_presentation_jun10_2014.pdf
   Google Scholar
• Biro A. Good early results seen with anti-VEGF refillable port delivery system. OSN Retina 2013;Jan
   Google Scholar
• Gooch N, Molokhia SA, Condie R, et al. Ocular drug delivery for glaucoma management. Pharmaceutics 2012;4:197–211
   PubMedGoogle Scholar
• Avery RL, Saati S, Journey M, et al. A novel implantable, refillable pump for intraocular drug delivery. ARVO; 2010; Orlando, FL
   Google Scholar
• Gutierrez-Hernandez JC, Caffey S, Abdallah W, et al. One-year feasibility study of replenish micropump for intravitreal drug delivery: a pilot study. TVST 2014;3:1–13
   Google Scholar
• Saati S, Lo R, Li PY, et al. Mini drug pump for ophthalmic use. Trans Am Ophthalmol Soc 2009;107:60–71
   PubMedGoogle Scholar
• Lavik E, Kuehn MH, Kwon YH. Novel drug delivery systems for glaucoma. Eye 2011;25:578–86
   PubMed Web of Science ®Google Scholar
• Dalton M. Drug-delivery micropump for chronic retina disorders. Ophthalmol Times 2014 ;Nov
   Google Scholar
• Tao W. Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin Biol Ther 2006;6:717–26
   PubMedGoogle Scholar
• Kauper K, McGovern C, Sherman S, et al. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Ophthalmol Vis Sci 2012;53:7484–91
   PubMed Web of Science ®Google Scholar
• Edelhauser HF, Rowe-Rendleman CL, Robinson MR, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci 2010;51:5403–19
   PubMed Web of Science ®Google Scholar
• Phan CM, Hui A, Subbaraman L, Jones L. Insights to using contact lenses for drug delivery. Clin Exp Pharmacol 2014;4:145–8
   Google Scholar
• Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol 2013;2:47–64
   PubMedGoogle Scholar
• Kim HJ, Zhang K, Moore L, Ho D. Diamond nanogel-embedded contact lenses mediate lysozyme-dependent therapeutic release. ACS Nano 2014;8:2998–3005
   PubMed Web of Science ®Google Scholar
• Ciolino JB, Hoare TR, Iwata NG, et al. A drug-eluting contact lens. Invest Ophthalmol Vis Sci 2009;50:3346–52
   PubMed Web of Science ®Google Scholar
• Ciolino JB, Stefanescu CF, Ross AE, et al. In vivo performance of a drug-eluting contact lens to treat glaucoma for a month. Biomaterials 2014;35:432–9
   PubMed Web of Science ®Google Scholar
• Dixit N, Bali V, Baboota S, et al. Iontophoresis – an approach for controled drug delivery: a review. Curr Drug Deliv 2007;4:1–10
   PubMedGoogle Scholar
• Cohen AE, Assang C, Patane MA, et al. Avion Study Investigators. Evaluation of dexamethasone phosphate delivered by ocular iontophoresis for treating noninfectious anterior uveitis. Ophthalmology 2012;119:66–73
   PubMed Web of Science ®Google Scholar
• Patane MA, Cohen A, From S, et al. Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial. Clin Ophthalmol 2011;5:633--43
   PubMedGoogle Scholar
• Patane MA, Schubert W, Sanford T, et al. Evaluation of ocular and general safety following repeated dosing of dexamethasone phosphate delivered by transscleral iontophoresis in rabbits. J Ocul Pharmacol Ther 2013;29:760–9
   PubMed Web of Science ®Google Scholar
• EyeGate's EGP-437 matches the standard-of-care's response rate in phase III study in patients with anterior uveitis [press release]. April 9, 2013;2013
   Google Scholar
• Campochiaro P. Overview of ocular gene therapy. Washington D.C: American Society of Gene and Cell Therapy; 2010
   Google Scholar
• Boye SE, Boye SL, Lewin AS, Hauswirth WW. A comprehensive review of retinal gene therapy. Mol Ther 2013;21:509–19
   PubMed Web of Science ®Google Scholar
• Chalberg TW. Anti-VEGF gene therapy: early clinical results using the ocular biofactory in wet AMD. Symposium on Angiogenesis, Exudation, and Degeneration February 8, 2014; Miami, FL
   Google Scholar
• Binley K, Widdowson PS, Kelleher M, et al. Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat®, for age-related macular degeneration. Hum Gene Ther 2012;23:980–91
   PubMed Web of Science ®Google Scholar
• Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009;61:158–71
   PubMed Web of Science ®Google Scholar
• Brazzell K, Schopf L, Enlow E, et al. Evaluation of pharmacokinetic profile of novel ophthalmic formulation of loteprednol etabonate. The American Society of Cataract and Refractive Surgery/ASOA Symposium and Congres; 2014; Boston, MA
   Google Scholar
• Schopf L, Enlow E, Popov A, et al. Enhanced topical delivery of a small molecule receptor tyrosine kinase inhibitor (RTKi) via mucosal-penetrating particle technology. Invest Ophthalmol Vis Sci 2013;54:E-Abstract 1087
   Google Scholar
• Wong TT, Novack GD, Ho CL, et al. A pilot study of the ocular hypotensive efficacy and safety of a subconjunctival injection of liposomal ltanoprost. American Glaucoma Society Annual Meeting; 2014 Feb 27–Mar 2; Washington DC
   Google Scholar
• Patel SR, Berezovsky DE, McCarey BE, et al. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci 2012;53:4433–41
   PubMed Web of Science ®Google Scholar
• O’Rourke M. Graybug ophthalmology innovation summit. Ophthalmology Innovation Summit; 2014; Chicago, IL
   Google Scholar
• Kuno N, Fujii S. Recent advances in ocular drug delivery systems. Polymers 2011;3:193–221
   Web of Science ®Google Scholar
• Haghjou N, Soheilian M, Abdekhodaie MJ. Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res 2011;6:317–29
   PubMedGoogle Scholar